Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.

[1]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[2]  J. Hollander,et al.  B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  T. McDonagh,et al.  Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. , 2003, Journal of the American College of Cardiology.

[4]  P. Buser,et al.  B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure? , 2002, Swiss medical weekly.

[5]  M. Redfield,et al.  Heart failure--an epidemic of uncertain proportions. , 2002, The New England journal of medicine.

[6]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[7]  J. Hollander,et al.  B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study , 2002, Circulation.

[8]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[9]  R. Pistelli,et al.  Exacerbated chronic obstructive pulmonary disease: a frequently unrecognized condition , 2002, Journal of internal medicine.

[10]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[11]  L. Morrison,et al.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea ☆ , 2002 .

[12]  John A Spertus,et al.  Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. , 2002, Journal of the American College of Cardiology.

[13]  M. Vogeser,et al.  Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[14]  D. Dusser,et al.  Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. , 2001, Chest.

[15]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[16]  J. Carroll,et al.  Heart Failure With a Normal Ejection Fraction: Is Measurement of Diastolic Function Necessary to Make the Diagnosis of Diastolic Heart Failure? , 2001, Circulation.

[17]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[18]  L. Lenert,et al.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.

[19]  U. Dohrmann,et al.  Gene Expression of Brain Natriuretic Peptide in Isolated Atrial and Ventricular Human Myocardium: Influence of Angiotensin II and Diastolic Fiber Length , 2000, Circulation.

[20]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[21]  S. Ogston,et al.  Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea , 1997, BMJ.

[22]  M. Sorrentino,et al.  Causes of congestive heart failure. Prompt diagnosis may affect prognosis. , 1997, Postgraduate medicine.

[23]  Milton C. Weinstein,et al.  Recommendations for Reporting Cost-effectiveness Analyses , 1996 .

[24]  M C Weinstein,et al.  Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[25]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[26]  H. Itoh,et al.  Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. , 1995, Circulation.

[27]  B. Gersh,et al.  The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. , 1995, The American journal of cardiology.

[28]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[29]  A. Richards,et al.  Plasma brain natriuretic peptide in assessment of acute dyspnoea , 1994, The Lancet.

[30]  R. Wuerz,et al.  Effects of prehospital medications on mortality and length of stay in congestive heart failure. , 1992, Annals of emergency medicine.